Now Reading:

Sanofi ups its bid to buy Genzyme


Sanofi ups its bid to buy Genzyme


French pharmaceuticals group Sanofi-Aventis has made a new bid to buy US biotech company Genzyme. Sanofi is offering 71 dollars a share, or just over 55 euros. That is two dollars a share more than an offer Sanofi made last month. It hopes the new valuation will be enough to get Genzyme to open its books as part of “partial due diligence.”

Every story can be told in many ways: see the perspectives from Euronews journalists in our other language teams.

Next Article